Jorey Chernett Acquires 45,600 Shares of AirSculpt Technologies (NASDAQ:AIRS) Stock

AirSculpt Technologies, Inc. (NASDAQ:AIRS) major shareholder Jorey Chernett bought 45,600 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were bought at an average cost of $2.00 per share, for a total transaction of $91,200.00. Following the transaction, the insider owned 6,398,211 shares in the company, valued at approximately $12,796,422. The trade was a 0.72% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Wednesday, March 4th, Jorey Chernett purchased 30,000 shares of AirSculpt Technologies stock. The stock was bought at an average price of $1.87 per share, with a total value of $56,100.00.
• On Tuesday, March 3rd, Jorey Chernett acquired 80,000 shares of AirSculpt Technologies stock. The shares were purchased at an average cost of $1.71 per share, with a total value of $136,800.00.

AirSculpt Technologies Stock Down 6.8%

NASDAQ AIRS opened at $1.92 on Wednesday. The company has a quick ratio of 0.51, a current ratio of 0.51 and a debt-to-equity ratio of 0.63. AirSculpt Technologies, Inc. has a 52 week low of $1.51 and a 52 week high of $12.00. The firm has a market capitalization of $119.88 million, a price-to-earnings ratio of -6.40 and a beta of 2.75. The company has a fifty day moving average of $2.20 and a two-hundred day moving average of $4.78.

Institutional Trading of AirSculpt Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in shares of AirSculpt Technologies during the fourth quarter valued at $30,000. Millennium Management LLC bought a new position in shares of AirSculpt Technologies in the fourth quarter worth about $33,000. Aigen Investment Management LP purchased a new position in AirSculpt Technologies in the 4th quarter worth about $36,000. Wells Fargo & Company MN increased its stake in AirSculpt Technologies by 49.9% in the 4th quarter. Wells Fargo & Company MN now owns 19,275 shares of the company’s stock worth $38,000 after buying an additional 6,420 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in AirSculpt Technologies by 239.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,952 shares of the company’s stock valued at $48,000 after buying an additional 4,199 shares in the last quarter. Hedge funds and other institutional investors own 91.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AirSculpt Technologies in a research note on Monday, December 29th. Leerink Partners reissued a “market perform” rating and issued a $6.00 price objective on shares of AirSculpt Technologies in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, AirSculpt Technologies currently has an average rating of “Reduce” and an average target price of $6.00.

AirSculpt Technologies Company Profile

AirSculpt Technologies, Inc (NASDAQ: AIRS) is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction.

Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.